Patricia Teeter
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,242 of the $12,846 with a category attached, or 64.2%. 35 manufacturers reported payments, led by TG Therapeutics, Inc. at 38.7% of the total. Reporting peaked in 2024 at $6,101 and has fallen 56.9% since, to $2,628 in 2025. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 488 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$5K
- Biogen$1K
- Novartis$1K
- EMD Serono, Inc.$766
- Sanofi$702
- AbbVie$689
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,2159%
- Speaking & faculty fees$3,07724%
- Food & beverage$8,24264%
- Education$3122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 29 | $4,976 |
| Biogen | 89 | $1,289 |
| Novartis | 101 | $1,272 |
| EMD Serono, Inc. | 41 | $766 |
| Sanofi | 26 | $702 |
| AbbVie(2 entities) | 39 | $689 |
| Bristol Myers Squibb | 41 | $567 |
| Lilly USA, LLC | 22 | $378 |
| Genentech USA, Inc. | 16 | $330 |
| Banner Life Sciences, LLC | 7 | $298 |
| Johnson & Johnson | 5 | $167 |
| ANI Pharmaceuticals, Inc. | 8 | $149 |
| Mallinckrodt Hospital Products Inc. | 7 | $135 |
| Vanda Pharmaceuticals Inc. | 5 | $133 |
| Otsuka America Pharmaceutical, Inc. | 7 | $127 |
| Piramal Critical Care | 1 | $120 |
| Ipsen Biopharmaceuticals, Inc | 6 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $89 |
| Pfizer | 5 | $78 |
| Lundbeck LLC | 4 | $72 |
| Cycle Pharmaceuticals Inc | 3 | $53 |
| Amgen(2 entities) | 2 | $39 |
| Medtronic | 1 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Nalu Medical, Inc. | 2 | $30 |
| Biodelivery Sciences International, Inc. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,846 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 57 | $527,200 |
| AubagioTeriflunomide | 39 | $356,806 |
| VumerityDiroximel Fumarate | 12 | $120,305 |
| CopaxoneGlatiramer Acetate | 15 | $87,288 |
| NuedextaDextromethorphan Hbr/Quinidine | 46 | $85,118 |
| Teriflunomide | 11 | $65,994 |
| Glatiramer Acetate | 13 | $23,229 |
| MyrbetriqMirabegron | 47 | $20,849 |
| Dalfampridine ErDalfampridine | 58 | $16,152 |
| QuliptaAtogepant | 12 | $15,261 |
| Baclofen | 137 | $3,524 |
| Modafinil | 26 | $1,508 |
| Carbamazepine | 17 | $1,383 |
| Duloxetine Hcl | 27 | $952 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $702 | $356,80639 claims |
| BiogenVumerity | $1,289 | $120,30512 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $31 | $85,11846 claims |
| AbbVieQulipta | $689 | $15,26112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.
Other family in Wahoo
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Mary MetzLincoln$13K
- Sara LegleiterOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.